135 related articles for article (PubMed ID: 17576839)
1. In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.
Lortholary O; Dannaoui E; Raoux D; Hoinard D; Datry A; Paugam A; Poirot JL; Lacroix C; Dromer F;
Antimicrob Agents Chemother; 2007 Sep; 51(9):3378-80. PubMed ID: 17576839
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
3. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer.
Bagg J; Sweeney MP; Davies AN; Jackson MS; Brailsford S
J Med Microbiol; 2005 Oct; 54(Pt 10):959-964. PubMed ID: 16157550
[TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
6. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
8. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2008 Feb; 46(2):551-9. PubMed ID: 18094129
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
Gupta AK; Kohli Y; Batra R
Med Mycol; 2005 Mar; 43(2):179-85. PubMed ID: 15832561
[TBL] [Abstract][Full Text] [Related]
10. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Bijie H; Dzierzanowska D; Klimko NN; Letscher-Bru V; Lisalova M; Muehlethaler K; Rennison C; Zaidi M;
J Clin Microbiol; 2009 Jan; 47(1):117-23. PubMed ID: 19005141
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
[TBL] [Abstract][Full Text] [Related]
12. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.
Minea B; Nastasa V; Moraru RF; Kolecka A; Flonta MM; Marincu I; Man A; Toma F; Lupse M; Doroftei B; Marangoci N; Pinteala M; Boekhout T; Mares M
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):367-83. PubMed ID: 25224578
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of fluconazole, voriconazole, and MXP-4509 against Romanian blood yeast isolates.
Mareş M; Năstasă V; Ramona FM; Doroftei B; Stefanache A
Mycopathologia; 2011 Dec; 172(6):487-92. PubMed ID: 21805354
[TBL] [Abstract][Full Text] [Related]
14. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
17. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.
Wang H; Xiao M; Chen SC; Kong F; Sun ZY; Liao K; Lu J; Shao HF; Yan Y; Fan H; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Xu YC
J Clin Microbiol; 2012 Dec; 50(12):3952-9. PubMed ID: 23035204
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
